Improved treatment of early small hepatocellular carcinoma using sorafenib in combination with radiofrequency ablation

Gong,Quanyou; Qin,Zhaoxia; Hou,Fangli

doi:10.3892/ol.2017.7174

Improved treatment of early small hepatocellular carcinoma using sorafenib in combination with radiofrequency ablation

Authors:
- Quanyou Gong
- Zhaoxia Qin
- Fangli Hou
View Affiliations

Affiliations: Department of Intensive Care Unit, Zhumadian Central Hospital, Zhumadian, Henan 463000, P.R. China, Department of Urology, Zhumadian Central Hospital, Zhumadian, Henan 463000, P.R. China
Published online on: October 12, 2017 https://doi.org/10.3892/ol.2017.7174
Pages: 7045-7048
Copyright: © Gong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Small hepatocellular carcinoma is an important leading cause of death amongst cancer patients, our study was designed in order to test the hypothesis that radiofrequency ablation (RFA) combined with a chemotherapeutic drug would improve the outcome for patients. Two groups of patients presenting early small hepatocellular carcinoma were treated with either conventional RFA alone (50 individuals in the control group), or with a combination of RFA and oral sorafenib (40 individuals in an observation group). Individual clinical and laboratory evaluations were done during an average follow-up time of 35 months, and all the data recorded was used to compare results of both treatment approaches. Tumor‑free survival, relapse rate and survival rate, RFA interval and number of treatments, overall efficacy and the incidence of complications were analyzed. Serum levels of vascular endothelial growth factor (VEGF), connective tissue growth factor (CTGF), hypoxia inducible factor-1α (HIF‑1α) and osteopontin (OPN) were measured and compared. Our results show that the patients in the treatment group had statistically significant prolonged tumor‑free survival, decreased relapse and increased survival rates. Also, the patients in the treatment group had significantly more prolonged average intervals of RFA and a lower number of treatments. Furthermore, the overall efficacy in the treatment group was increased, yet the incidence of complications was similar between both groups. Moreover, the serum levels of known tumorigenic factors VEGF, CTGF, HIF-1α and OPN, which were similar between both groups before treatment, improved more markedly after the treatment in the observation group patients. Based on these findings, we propose that sorafenib in combination with percutaneous RFA is safe and efficacious, and a superior treatment for early small hepatocellular carcinoma. Larger studies are needed to corroborate our results.

View Figures

View References

1	Yung KW, Yung TT, Chung CY, Tong GT, Liu Y, Henderson J, Welbeck D and Oseni S: Principles of cancer staging. Asian Pac J Surg Oncol. 1:1–16. 2015.
2	Zheng YF, Tan LK, Tan BH, Sterling H and Kane R: Principles of surgical oncology. Asian Pac J Surg Oncol. 1:17–26. 2015.
3	Dobson PR, Brown BL, Beck D, Yang H, Zhou J and Voon YL: Management of surgical oncologic emergencies. Asian Pac J Surg Oncol. 1:59–72. 2015.
4	Li WW, Dai ZY, Wan HG, Yao LZ, Zhu J, Li CL, Wang XJ, Pan J and Chen LZ: Endovascular implantation of iodine-125 seeds strand and portal vein stenting followed by transcatheter arterial chemoembolization combined therapy with sorafenib for hepatocellular carcinoma with main portal vein tumor thrombus. Zhonghua Yi Xue Za Zhi. 96:1838–1842. 2016.(In Chinese). PubMed/NCBI
5	Dinh VY, Bhatia S, Narayanan G, Yrizarry J, Savaraj N, O'Brien C, Martin P and Feun L: Pilot study of intrahepatic artery chemotherapy in combination with sorafenib in hepatocellular carcinoma. Anticancer Res. 36:3555–3563. 2016.PubMed/NCBI
6	Hatooka M, Kawaoka T, Aikata H, Morio K, Kobayashi T, Hiramatsu A, Imamura M, Kawakami Y, Murakami E, Waki K, et al: Comparison of outcome of hepatic arterial infusion chemotherapy and sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Anticancer Res. 36:3523–3529. 2016.PubMed/NCBI
7	Cahill T, Chen XL, Lee JW, Weiss M, Chang VT and Cella D: Principles of radiofrequency ablation for cancer. Asian Pac J Surg Oncol. 1:47–58. 2015.
8	Ghoneum M, Felo N, Nwaogu OM, Fayanju IY, Jeffe JA and Margenthaler DB: Clinical trials in surgical oncology. Asian Pac J Surg Oncol. 1:73–82. 2015.
9	Sterling B, Cole R, Jen KK and Shieh JS: Surgical oncology in the elderly. Asian Pac J Surg Oncol. 1:83–100. 2015.
10	Mellotte G, Maher V, Devitt PG, Shin VY and Leung CP: Minimally invasive surgical oncology: state of the art. Asian Pac J Surg Oncol. 1:101–112. 2015.
11	Sheta E, El-Kalla F, El-Gharib M, Kobtan A, Elhendawy M, Abd-Elsalam S, Mansour L and Amer I: Comparison of single-session transarterial chemoembolization combined with microwave ablation or radiofrequency ablation in the treatment of hepatocellular carcinoma: a randomized-controlled study. Eur J Gastroenterol Hepatol. 28:1198–1203. 2016. View Article : Google Scholar : PubMed/NCBI
12	Fujiwara H, Arai Y, Ishii H and Kanazawa S: Computed tomography-guided radiofrequency ablation for sub-diaphragm hepatocellular carcinoma: safety and efficacy of inducing an artificial pneumothorax. Acta Med Okayama. 70:189–195. 2016.PubMed/NCBI
13	Sohn W, Kang TW, Choi SK, Jung SH, Lee MW, Lim HK, Cho JY, Shim SG, Sinn DH, Gwak GY, et al: Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. Oncotarget. 14:17–18. 2016.
14	Borentain P, Gregoire E, Louis G and Gerolami R: Successful liver transplantation for hepatocellular carcinoma following down-staging using sorafenib single therapy. Liver Int. 36:13932016. View Article : Google Scholar : PubMed/NCBI
15	Shiozawa K, Watanabe M, Ikehara T, Kogame M, Kikuchi Y, Igarashi Y and Sumino Y: Therapeutic evaluation of sorafenib for hepatocellular carcinoma using contrast-enhanced ultrasonography: preliminary result. Oncol Lett. 12:579–584. 2016.PubMed/NCBI
16	Xia F, Wu LL, Lau WY, Huan HB, Wen XD, Ma KS, Li XW and Bie P: Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. World J Gastroenterol. 22:5384–5392. 2016. View Article : Google Scholar : PubMed/NCBI
17	Zeng J, Lv L and Mei ZC: Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol. 20:18–19. 2016.
18	Ishikawa T, Kubota T, Abe S, Watanabe Y, Sugano T, Inoue R, Iwanaga A, Seki K, Honma T and Yoshida T: Hepatic arterial infusion chemotherapy with cisplatin before radical local treatment of early hepatocellular carcinoma (JIS score 0/1) improves survival. Ann Oncol. 25:1379–1384. 2014. View Article : Google Scholar : PubMed/NCBI
19	Guo W, He X, Li Z and Li Y: Combination of transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) vs. surgical resection (SR) on survival outcome of early hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology. 62:710–714. 2015.PubMed/NCBI
20	Zhu AX, Kang YK, Rosmorduc O, Evans TR, Santoro A, Ross P, Gane E, Vogel A, Jeffers M, Meinhardt G, et al: Biomarker analyses of clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib with or without erlotinib in the SEARCH trial. Clin Cancer Res. 24:182–183. 2016.
21	Lamarca A, Mendiola M, Bernal E, Heredia V, Díaz E, Miguel M, Pastrian LG, Burgos E, Feliu J and Barriuso J: Tumoural expression of connective tissue growth factor (CTGF) impacts on survival in patients diagnosed with hepatocellular carcinoma (HCC). Curr Cancer Drug Targets. 15:435–444. 2015. View Article : Google Scholar : PubMed/NCBI
22	Ma L, Li G, Zhu H, Dong X, Zhao D, Jiang X, Li J, Qiao H, Ni S and Sun X: 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and −2. Cancer Lett. 355:96–105. 2014. View Article : Google Scholar : PubMed/NCBI
23	Dong Q, Zhu X, Dai C, Zhang X, Gao X, Wei J, Sheng Y, Zheng Y, Yu J, Xie L, et al: Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin. Oncotarget. 7:12997–13012. 2016. View Article : Google Scholar : PubMed/NCBI